We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent
An SI Board Since September 2019
Posts SubjectMarks Bans Symbol
23 1 0 ACRS
Emcee:  BioHero Type:  Moderated
BRUTAL Hot Rebound Play which is massive underpriced here trading wayyy below cash ....

Market Cap $43 M / Cash $115 M or untill end 2021 / 2 Marketed Product / 1 Phase 3 trial (common warts) with results expected in Q4 2019 and many other phase 2 programs / because of their strategic change they wants to out-license all their Products which means HUGE upfront payments for the company (more infos below)= CHEAPEST Biotech you can get at this time

Aclaris Therapeutics (ACRS)

Market Cap: $43 M
Cash: $115 M or enough untill end 2021

Price $1.07

Aclaris Therapeutics Announces New Strategic Direction

ACRS aquired a attractive drug from Allergan last year paid $65 m upfront alone for this drug which they now looking to outlicense .


Largest Shareholders:

Deerfield Management Company LP...5 893 416
Franklin Advisers, Inc....3 953 203
BlackRock Fund Advisors ...2 359 223
Broadfin Capital LLC...2 280 260
D. E. Shaw & Co. LP....2 049 462
Sofinnova Ventures, Inc.....1 911 573
Vivo Capital LLC ....1 647 214
Fidelity Management & Research Co...1 562 190
Polar Capital LLP...1 443 920
The Vanguard Group, Inc...1 142 022
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
23William Blair sees 'significant value disconnect' in Aclaris TherapeuticBioHero-10/11/2019
22Great News out ...could hit $2 today...up 26% in pre mkt Aclaris TherapeuticBioHero-10/11/2019
21ACRS..Eskata approval likely next week guys , 10 months review timeline like in BioHero-10/10/2019
20$2++ coming and going wayyy higher on Partnership news and Phase 3 resultsBioHero-10/7/2019
19Price $1.13 ...Market cap $45 Million ...Cash $115Million ...Book Value $3.30 ..BioHero-10/7/2019
18Major breakout coming .... [graphic]BioHero-10/4/2019
17What you get for the Market Cap of laughable $42 Million = you get $115 M of CasBioHero-10/3/2019
16Book Value $3.30 / Cash per Share $2.79 / 2+ years of Cash / 2 Approved Drugs / BioHero-9/30/2019
15New presentation investor.aclaristx.comBioHero-9/27/2019
14With One Late-Stage Study Out Of The Way, Aclaris Moves One Inch Closer To CommeBioHero-9/26/2019
13next breakout to $2+comingBioHero-9/25/2019
12Eskata approval in Canada expected within 3 Weeks will trigger milestone paymentBioHero-9/25/2019
11With $115 Million Cash or untill late 2021 and more Cash + Royalties from partneBioHero-9/24/2019
10still a mega buying opportunity here trading massive below cashBioHero-9/23/2019
9if your a shareholder please put a high gtc sell order in $5 or higher .thank yoBioHero-9/20/2019
8great buying opp again here ,, more news coming shortly like partner deals and sBioHero-9/19/2019
7Up 100% and still trading below cash ($2.80 Cash per share )BioHero-9/17/2019
6BOOOOOOOOOOOOOOOOOOOOOOOM and still trading below cash which alone is $2.80 per BioHero-9/16/2019
5POSITIVEE PHASE 3 RESULTS YIPPIIIIIIIIIIIIIII Aclaris Therapeutics’ A-101 45% TBioHero-9/16/2019
4New Major breakout to $2+ could starty anytime now wh [graphic]BioHero-9/16/2019
3Morgan Stanley reports 5% passive stake in Aclaris Therapeutics...08/29,2019 theBioHero-9/13/2019
2the cheapest biotech you can get trading massive under cash who has 2 approved dBioHero-9/13/2019
1great rebound stock which could triple easily [graphic]BioHero-9/12/2019
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):